Table 1 Socio-demographic and clinical features of 33 patients (66 eyes) with Vogt-Koyanagi-Harada disease followed for 12 months since acute disease onset
Features | Presence of BALAD at baseline (n = 56 eyes) | P | ||
|---|---|---|---|---|
Yes (n = 27 eyes) | No (n = 29 eyes) | |||
Age at disease onset, years, mean ± SD | 33.6 ± 11 | 32.07 ± 8.6 | 32.9 ± 7.6 | 0.756 |
median (interval) | 33 (15–67) | 35 (15–45) | 32 (15–46) | |
Male/Female, n (%) | 4 (12) /29 (88) | 2/15 | 2/16 | |
Interval to treatment start, days, mean ± SD | 24.4 ± 16.0 | 21.48 ± 11.18 | 24.55 ± 15.19 | 0.483 |
median (range) | 21 (3–67) | 21 (8–48) | 21 (3–51) | |
Disease duration, months, mean ± SD | 89.9 ± 25.9 | 84.2 ± 24.17 | 86.9 ± 23.25 | 0.721 |
median (interval) | 85 (45–139) | 83 (45–139) | 82 (45–126) | |
Visual acuity, logMAR, at M0 mean ± SD | 1.3 ± 0.8 | 1.6 ± 0.8 | 1.09 ± 0.8 | 0.058 |
median (interval) | 1.8 (0–2.3) | 1.8 (0–2.3) | 0.8 (0–2.3) | |
at M1 mean ± SD | 0.4 ± 0.7 | 0.32 ± 0.48 | 0.31 ± 0.56 | 0.532 |
median (interval) | 0.2 (0–2) | 0.2 (0–2) | 0.1 (0–2) | |
at M12 mean ± SD | 0.05 ± 0.1 | 0.001 ± 0.008 | 0.0607 ± 0.16 | 0.214 |
median (interval) | 0 (0–0.7) | 0 (0–0.04) | 0 (0–0.7) | |
Fluorescein angiography total score at baseline | 0.708 | |||
mean ± SD | 6.7 ± 2.9 | 8.08 ± 2.03 | 6.04 ± 2.96 | |
median (interval) | 8 (0–13) | 9 (4–13) | 7 (0–9) | |
Full-field electroretinogram at M12, eyes (%) a | ||||
Subnormal | 47 (75.8) | 20 (74.0) | 18 (62.0) | 0.319 |
Treatment, patients (%) | 0.823 | |||
Corticosteroid monotherapy | 10 (30.0) | 4 (12) | 6 (18) | |
Corticosteroid + early immunosuppressive therapy (≤ 1mo) | 11 (34.0) | 5 (16) | 6 (18) | |
Corticosteroid + late immunosuppressive therapy (> 1mo) | 12 (36.0) | 8 (24) | 4 (12) | |
Fundus outcomes in the first year of disease, eyes (%) | ||||
Subretinal fibrosis | 20 (30) | 14 (51.9) | 4 (13.8) | < 0.001 |
Sunset glow fundus | 38 (57.5) | 22 (81.5) | 12 (41.4) | 0.008 |
Atrophic nummular lesions | 26 (39.3) | 14 (51.9) | 8 (27.6) | 0.278 |